


# Obesity : not just a matter of food

ARNOULD Thierry  
University of Namur  
May 19, EFID 2016

Less than 30 years  
Evolution ???



Unité de Recherche en Biologie Cellulaire (URBC)  
Namur Research Institute for Life Sciences  
(NARILIS)  
University of Namur

*Homo sapiens  
sapiens*


*Homo sapiens  
obesus  
diabeticus*

# Obesity : a multifactorial problem

What is your problem buddy ?

Your food ? Your genes ? Your epigenetics? Your brain ? Your life style? Your microbiota?...

ob/ob



# Obesity

1. **Obesity : definition, epidemiology, distribution**
2. **The role of the brain and CNS in food intake control**
3. **Obesity and associated diseases : co-morbidities**
4. **Adipose tissues and their role in obesity**
5. **Genetic control of body mass**
6. **The importance of the microbiota**
7. **Thermoregulation and UCPs : an energy dissipating mechanism**
8. **Management of obesity**



# The Healthcare Costs of Obesity




Obesity is one of the biggest drivers of preventable chronic diseases and healthcare costs in the United States. Currently, estimates for these costs range from \$147 billion to nearly \$210 billion per year.<sup>1</sup> In addition, obesity is associated with job absenteeism, costing approximately \$4.3 billion annually<sup>2</sup> and with lower productivity while at work, costing employers \$506 per obese worker per year.<sup>3</sup>

<http://stateofobesity.org/healthcare-costs-obesity/>

## Metabolic syndrome:

- Hypertriglyceridemia
- Increased LDL level
- Decreased HDL level
- Hypertension
- Hyperglycemia
- Insulin resistance




**OBESITY is no laughing matter**

Obesity is today's critical national public health problem. Nearly two thirds of men and half of women are overweight or obese.

- 15 million sick days and 40,000 lost years working life.
- Direct cost to the NHS - £12 billion (indirect costs £2 billion).
- Particulate and action required now to avert this serious medical condition.
- Obesity is the 2nd largest cause of cancer after smoking.
- Obese people live on average nine years less.

Telephone: 0115 8462109  
[www.nationalobesityforum.org.uk](http://www.nationalobesityforum.org.uk)

# Obesity in the world : increases and affects childs



**Historic, current and projection for obesity prevalence**

**(International Obesity Task Force)**

**Average O/OW in adult populations :**

**USA : > 66 % (2014)**

> 2 in 3 adults are overweight or obese.

➤ > 33 % of adults are obese.

➤ > 5 % of adults are extremely obese.

➤ > 1/3 of children and adolescents ages 6 to 19 are considered to be overweight or obese.

➤ > 1 in 6 children and adolescents ages 6 to 19 are considered to be obese.

**EU : 37-56% F and 51-69% M (2010)**

**(Roumania : 15% lower versus UK)**

**Rapid growth...**

**UK : 6 % H (80) ---> 17 % (97)**

**8 % F (80) ---> 20 % (97)**

**Asia : Japan-China : increasing but lower**



Classification	BMI (kg/m <sup>2</sup> )	
	Principal cut-off points	Additional cut-off points
Underweight	<18.50	<18.50
Severe thinness	<16.00	<16.00
Moderate thinness	16.00-16.99	16.00-16.99
Mild thinness	17.00-18.49	17.00-18.49
Normal range	18.50-24.99	18.50-22.99 23.00-24.99
Overweight	≥ 25.00	≥ 25.00
Pre-obese	25.00-29.99	25.00-27.49 27.50-29.99
Obese	≥ 30.00	≥ 30.00
Obese class I	30.00-34.99	30.00-32.49 32.50-34.99
Obese class II	35.00-39.99	35.00-37.49 37.50-39.99
Obese class III	≥ 40.00	≥ 40.00


# Obesity and overweight classification: BMI

The shift from fat to carbohydrates ? (*Science* 291 (2001) : 2536)

**BMI / IMC : mass (Kg) / [ height (m)]<sup>2</sup> ≥ 30**

**---> > 35 % in the US (Coca-Colanized countries)**

**---> > 60 % are obese or overweight**



## Classification of overweight (WHO experts)

BMI (Kg/m <sup>2</sup> )	WHO	Popular
< 18.5	UW	thin
18.5-24.9	N	healthy
25-29.9	G1/ OW	overweight
30.0-39.9	G2/ OW	obesity
≥ 40	G3/ OW	morbid obesity

## Obesity prevalence in 2014

No state had a prevalence of obesity less than 20%.

5 states and the District of Columbia had a prevalence of obesity between 20% and <25%.


23 states, Guam and Puerto Rico had a prevalence of obesity between 25% and <30%.

19 states had a prevalence of obesity between 30% and <35%.


3 states (Arkansas, Mississippi and West Virginia) had a prevalence of obesity of 35% or greater.

**1958 : first textbook on cholesterol-  
The low-fat gospel : "In America, we no longer  
fear God or the Communists, but we fear fat"  
(D. Kritechvsky- Winstar Institute)**


# Are we all equals ?




Whites



Blacks



Hispanics




**Figure 4: Fat distribution Influences.** Fat distribution can be estimated by measurements of the ratio of waist to the hip circumference (WHR). Obese people with low WHR (subcutaneous or pear-shaped obesity) are at low risk for metabolic complications of obesity, whereas people with high WHR (visceral or apple-shaped obesity) are at high risk for these complications (based on Gesta *et al.*, 2007).

- BMI :  $\geq 30 \text{ kg/m}^2$
- Waist circumference (WC) :  $> 90 \text{ cm}$
- Waist-to-hip ratio (WHR) :  $\geq 0.9$
- Waist-to-height (WHtR) :  $> 0.5$
- MRI : Abdominal CT images

Normal



Obese




Obese




Normal

# Obesity is a complex and most likely multifactorial state





A man of 70 kg :  
 $\pm 2200 \text{ kCal/day} : 1400 \text{ kcal/day (BMR)}$   
 Brain and liver : 45 + 19 %



**Risk factors:**



- Genetic background
- Lifestyle
- Environment (foetal programming and maternal undernutrition)
- Gut microbiota

Obesity → Excessive accumulation of adipose tissue

Increase in fat cell volume (*hypertrophy*) and/or the number of adipose cells (*hyperplasia*)

# Life expectancy decreases when BMI increases

Person of 70 kg : 15 kg of fat in adipose tissues



Organ	Mass (g)	En (Kcal)
Fat (AT)	15.000	140.000
Proteins (M)	6000	24.000
Glycogen (M)	400	1600
Glycogen (L)	80	320

Fuel reservoirs of a normal 70 kg man after overnight fasting

**« We are what we eat »**  
**« Why do we need to eat? What ? and How much...? »**

**TABLEAU 2.1 Éléments naturels entrant dans la composition du corps humain**

Symbole chimique	Élément	Numéro atomique (voir la p. 30)	Pourcentage de la masse corporelle
O	Oxygène	8	65,0
C	Carbone	6	18,5
H	Hydrogène	1	9,5
N	Azote	7	3,3
Ca	Calcium	20	1,5
P	Phosphore	15	1,0
K	Potassium	19	0,4
S	Soufre	16	0,3
Na	Sodium	11	0,2
Cl	Chlore	17	0,2
Mg	Magnésium	12	0,1

Autres éléments à l'état de trace (moins de 0,01 %) : bore (B), chrome (Cr), cobalt (Co), cuivre (Cu), fluor (F), iode (I), fer (Fe), manganèse (Mn), molybdène (Mo), sélénium (Se), silicium (Si), étain (Sn), vanadium (V) et zinc (Zn).

C, O, H, N = 96 %

Ca, P, S, K, Na, Cl, Mg = ± 4 %

*Trace elements* : but essentials

Fe : essential

I : Thyroxine

B, Cr, Co, Cu, F, Mn, Mo, Se,...

**Quantitative and Qualitative aspects of food :**

**Proteins**

**Lipids**

**Carbohydrates**

**Nucleic acids : almost no contribution to fuels**

**« If not enough...or too much...or too much of some... »**

**--> Impair Functions --> Diseases**

- **Optimal life : healthy lifespan**
- **Optimal capacity : physical and intellectual**

**« lower calorie diet »**

# Energy and Syntheses

## FUELS

Carbohydrates ( $\pm 45-55\%$ )

Lipids ( $\pm 30-45\%$ )

Proteins ( $\pm 10-15\%$ )

+

H<sub>2</sub>O

*FACILITATION*

Vitamins

—————→ Uses

Minerals

*REGULATION*

↗ Energy

↘ Syntheses

Energy expenditures :

Basal Metabolism at Rest (BMR)

*Growth, Repair, Syntheses, Reproduction...Turn-over*

Physical activity

Heat production : Mitochondrial Uncoupling

**WHO** : « *If you eat too much of one thing, you eat a lot less of something else. So for every theory saying that this disease is caused by an excess of x, you can produce an alternative theory saying it is a deficiency in y* ».

# Structures of FFA and sugars



**1 Palmitic 16**



**Stearic 18**



**Oleic 18 (n-9)**




**Linolenic 18 (n-3)**




**Linoleic 18 (n-6)**


Polyunsaturated fatty acids are often classified into 'families' depending on the position of the first double bond counting back from the methyl end of the molecule. For example, linoleic acid is referred to as an n-6 fatty acid.




**PUF 20 (n-3)**



**PUF 22 (n-3)**




**Glucose**



**Fructose**


Disaccharides

**G - F**



**sucrose**


**G - G**



**maltose**

Modified carbohydrates


**Gal - G**




**lactose**

(glucose)


(sorbitol)



**sorbitol**



**malitol**



**xylitol**

## Large variety in european sugar consumption


*Average daily intakes of total sugars in six countries of the European Union*

<i>Country</i>	<i>g/day</i>	<i>% energy</i>
----------------	--------------	-----------------

1995

The Netherlands	131	21.2
United Kingdom	100	18.4
Belgium	96	15.2
Ireland	90	14.6
Germany	80	13.9
Spain	51	8.0

**Inverse relationship between intakes of sugars and fats in different affluent countries**




# The major fatty acids

<i>Symbol<sup>a</sup></i>	<i>Common name</i>	<i>Typical fat source</i>
<b><i>Saturated fatty acids</i></b>		
2:0	Acetic	Vinegar
4:0	Butyric	Butterfat
8:0	Caprylic	Palm kernel oil
10:0	Capric	Coconut oil
12:0	Lauric	Coconut oil
14:0	Myristic	Butterfat, coconut oil
16:0	Palmitic	Most fats and oils
18:0	Stearic	Most fats and oils
20:0	Arachidic	Lard, peanut oil
22:0	Behenic	"Caprenin"
<b><i>Unsaturated fatty acids</i></b>		
16:1 n-7	Palmitoleic	Fish oils
18:1 n-9 (cis)	Oleic	Most fats and oils
18:1 n-9 (trans)	Elaidic	Hydrogenated vegetable oils, butterfat, beef fat
18:2 n-6	Linoleic acid	Most vegetable oils
18:3 n-3	$\alpha$ -Linolenic	Soybean, canola oils
20:1 n-11	Gadoleic	Fish oils
20:3 n-9	Eicosatrienoic	Essential fatty acid-deficient animals
20:3 n-6	Dihomo-gamma-linolenic	
20:4 n-6	Arachidonic	Lard
20:5 n-3	Eicosapentaenoic	Fish oils
22:1 n-9	Erucic	Rapeseed oil
22:6 n-3	Docosahexaenoic	Fish oils

# Energy in Biomolecules

Oxidative reactions : *adjustment and multi-fuels*



**Yield : 25-40 %**

1 calorie = 4,184 Joule

Needs / day : 1800-3600 kcal / jour (2200-2800 kcal)

100 g of chips : 500 kcal

100 g of yoghurt : 62 kcal (= spent after 30 min of walking)

CH : 4 kcal/g

FAT : 9 kcal/g

PROTEIN : 4 kcal/g

Alcool : 7 kcal/g

# Metabolism and Basal Metabolism (BM)

*Metabolism : all biochemical reactions*

\* catabolism CH/F/P---> oxidation -----> energy

\* anabolism CH/F/P ---> syntheses -----> storage

*Basal Metabolism*

\*Quantity of energy spent at rest, awake, starved, and relaxed mentally and physically

- internal work : brain (20 %), heart, ventilation, peristaltic contraction, muscular tone,....

- temperature

\*  $\pm 1200-1800$  kcal / jour

*BM + meal (Resting Metabolic Rate)*

$\pm 200$  kcal

Factors tha influence the BM: size/height, age, sexe, endocrine activity,..

(kcal/g) :

CH : 4

Lipids : 9

Proteins : 4

Alcool : 7

Expenditures (/ BM)

sleeping : 1

studying : 1.4

walking : 2.5-5

skiing : 15

## Current views of sugars and obesity


*Diets rich in fat are more likely to promote the development of obesity than those rich in carbohydrates*

- 1) storage of fat is virtually illimited**
- 2) human beings have limited ability but still convert excess of CH to fat**
- 3) each gram of fat consumed has more than twice as many calories as each gram of CH**
- 4) satiety feeling is lower for fat**

**Apports quotidiens des principaux acides gras alimentaires chez des hommes d'âge moyen en Finlande, aux Pays-Bas, aux États-Unis et dans l'île de Corfou, en Grèce.**


	<b>Apports d'acides gras (g/jour)</b>			
	<b>Finlande</b>	<b>Pays-Bas</b>	<b>États-Unis</b>	<b>Corfou</b>
<b>Acides gras saturés</b>				
Acide laurique (C12:0)	4	2	2	0,3
Acide myristique (C14:0)	12	8	6	1,1
Acide palmitique (16:0)	38	30	30	16
Acide stéarique (C18:0)	20	15	14	3
Autres saturés*	7	6	4	2
<b>Acides gras mono-insaturés</b>				
Acide oléique ( <i>cis</i> -C18:1 $n$ -9)	40	29	37	56
<i>Trans</i> C16:1 + C18:1	5	7	4	0,2
<b>Acides gras poly-insaturés</b>				
Acide linoléique (C18:2 $n$ -6)	8	12	17	13
Acide $\alpha$ -linoléniq (C18:3 $n$ -3)	2	2	2	1
Acide eicosapentaénoïque (C20:5 $n$ -3)	0,4	0,3	0,1	0,2
Acide docosahexaénoïque (C22:6 $n$ -3)	0,3	0,1	0,1	0,6

# Total individual fat intake ( $\pm 55$ Kg/year =150 g/day 39 % of energy intake) -Germany-




# Alcohol as a source of energy

Beer




3.5–5.5% volume alcohol  
6.9–10.9 g

Wine




11–13% volume alcohol  
8.7–10.3 g

Fortified wine




17–22% volume alcohol  
8.1–10.4 g

Spirits  
eau de vie



40% volume alcohol  
7.6 g

# The TCA cycle and respiratory chain in a mitochondria




**Substrate oxidation in the TCA cycle activates the respiratory chain leading to the generation of ATP which is subsequently translocated to the cytosol.**


**ANT, adenine nucleotide translocator; GDH, glutamate dehydrogenase; Glu, glutamate; KG, ketoglutarate; OAA, oxaloacetate; PC, pyruvate carboxylase; PDH, pyruvate dehydrogenase; Suc-CoA, succinyl-CoA; SDH, succinate dehydrogenase; TCA, tricarboxylic acid; UCP2, uncoupling protein 2.**

# Formation of Acetyl-CoA, Malonyl-CoA and NADPH = precursors for lipid synthesis

Glycolysis





# Alcohol as an energetic fuel ?





# The adipose tissues : characteristics and functions



## White adipose tissue



## Beige adipose tissue



## Brown adipose tissue





<b>Mitochondrial content</b>	Low	High	High
<b>Lipid droplets</b>	One unilocular	Numerous	Numerous
<b>UCP-1 expression</b>	None or very low	High	High
<b>Thermogenic ?</b>	No	Yes	Yes
<b>Lipogenesis ?</b>	High	High	High
<b>Lipolysis</b>	Moderate	High	High

# Acetyl-CoA : a metabolic node with multiple functions and enzymatic pathways for TAG synthesis

- Oxidation of glucose excess
- $\beta$ -oxidation of excess FA
- Oxidation of ketogenic amino acid
- Oxidation of ethanol

TAG : 0.5 et 2 mmol/L  
or 0.45 et 1.75 g/L



1-Stearoyl, 2-linoleoyl, 3-palmitoyl glycerol,  
a mixed triacylglycerol

RDCI : 30 % (DCI : 40 % or more)

1 g of TG : 9 kCal


( ± 2200 kcal/day)

# The origin of fat cells in different fat depots


*PRDM16* controls the differentiation of brown adipocytes. The protein encoded by this gene is a zinc finger transcription factor.

Controls the cell fate/destiny between muscle and brown fat cells. Loss of the gene causes a loss of BAT and promotes muscle differentiation.


Differentiation step




PR-(PRD1-BF-RIZ1 homologous) domain protein 16=>PRDM16, the key factor in the differentiation of brown fat cells



# Progression of 3T3-L1 preadipocyte differentiation



**LPL, lipoprotein lipase;**  
**C/EBPs, CCAAT/enhancer binding proteins**  
**PPAR, peroxisome proliferator-activated receptor**  
**MIX, methylisobutylxanthine**  
**DEX, dexamethasone.**




## Ligands naturels


- Acides gras poly-insaturés (o 3)
  - Acide  $\alpha$ -linoléinique
  - Acide eicosapentaénoïque
  - Acide docosahexaénoïque
- Dérivés des prostaglandines J2 (PGJ2)
  - 15-déoxy- $\Delta^{12,15}$ -PGJ2
  - $\Delta^{12}$ -PGJ2

## Ligands synthétiques


- Thiazolidinediones (TZD)
  - Troglitazone
  - Roziglitazone (BRL49653)
  - Pioglitazone
- Anti-inflammatoires non stéroïdiens (AINS)
  - Ibuprofène
  - Fénoprofène



# Adipocyte TAG content is the result of a balance between lipolysis and lipogenesis



# Adipose tissues also play an important endocrine role



## Functions (anabolic hormone)

### *Carbohydrate metabolism*

#### Increase uptake of glucose

- \* glycogen synthesis
- \* inhibition of neoglucogenesis

### *Fat metabolism*

#### Increase fat storage in adipose tissue

- \* stimulates FA synthesis (glucose)
- \* inhibition of TAG hydrolysis
- \* inhibition of FA  $\beta$ -oxidation

### *Protein metabolism*

#### Increase protein synthesis

- \* promote the use of aa
- \* inhibits protein degradation

### *Hormone secretion*

- \* inhibition of glucagon secretion ( $\alpha$ -pancreatic cells)

## Modulators of the release


### *Stimulation*

- Blood glucose [ ]
- Intestinal glucose [ ]
- Glucagon level


### *Inhibition*

- Adrenaline
- Somatostatin

**Electron micrograph of part of a rat  $\beta$ -cell showing mitochondria (m) and insulin-containing secretory granules (sg).**



# Model for coupling of glucose metabolism to insulin secretion in the $\beta$ -cell




Glucose is phosphorylated by glucokinase (GK) and converted to pyruvate (Pyr). Pyruvate enters the mitochondria and fuels the TCA cycle, resulting in the transfer of reducing equivalents to the respiratory chain, leading to **hyperpolarization** of the mitochondrial membrane and generation of **ATP**. Subsequently, **closure of  $K_{ATP}$ -channels** depolarizes the cell membrane. This opens voltage-gated  $Ca^{2+}$  channels (VGCC), raising the cytosolic  $Ca^{2+}$  concentration ( $[Ca^{2+}]_c$ ), which triggers insulin exocytosis.

# Type II diabetes


Hyperinsulinemia / Hyperglycemia = insulin resistance

Glucose tolerance  
Glycemic index  
(G/F)




Time / injection G

Insulin sensitivity



Time / injection I

Insulin [ ]



Postprandial time

— Insulin

— Normal

— Resistance

# Insulin Signaling Pathway

Remodeling cortical actin  
 Generation of IP3  
 Recruitment of exocyst  
 components  
 Lipid rafts


Glucose  
 Transporter  
 (GLUT4)

AS 160  
 Rab-GTPase

Glucose metabolism  
 Glycogen/lipid/protein synthesis  
 Specific gene expression

Cell growth  
 Differentiation


General gene  
 expression



(Saltiel and Kahn, 2001)


# Mitochondria dysfunction and Insulin Resistance

Muscle cells




# Chronic Inflammation in WAT and Insulin Resistance


Guilherme-A et al., Nat Rev Mol Cell Biol. 2008;9(5):367-77



# Inflammation blocks TG accumulation in WAT




# Two hypothesis to explain the mechanisms linking obesity and insulin resistance






# Non-Shivering Adaptative Thermogenesis Activity of BAT in Human Adults

Lean subject with high BAT activity



<sup>18</sup>Fluorodeoxyglucose- PET/CT (computerized tomography)

↓  
**UCP1**




*Nedergaard et al., 2007 Am.J. Physiol Endocrinol. Metab.*  
*Van Marken Lichtenbelt et al, 2009 N.Engl. Med*  
*Cypess et al, 2009 N.Engl. Med*

# Non-Shivering Adaptative Thermogenesis

## Activity of BAT in Human Adults


Brown adipose-Tissue activity is negatively correlated with percentage of body fat

Lean subject  
with high BAT activity




**IRISIN** : an exercise-induced myokine, stimulates conversion of white into brown adipocytes as well as increased mitochondrial biogenesis and energy expenditure


Obese subject  
with very low BAT activity



# Adaptative thermogenesis in brown adipocytes



Mitochondria inner Membrane



UCP1 is located in the mitochondrial inner membrane where it uncouples substrate oxidation from ATP synthesis, thereby dissipating energy as **heat** (adaptive thermogenesis)

# Leptin and energy homeostasis

10 years :  $10^6$  kcalories

**Leptin :**

**Link between food and physiology.**

**Hormone secreted by adipocytes and active in neurons and periphery**

- **Controls food intake and body mass**

**Obese individuals :**


**Decrease in the leptin sensitivity**

**= resistance**


**- Reduction of passage through BBB**

**(low in brain / plasma)**

**- SOCS-3**




# Major hypothalamic regions implicated in adiposity signalling and food intake



**The Arcuate (ARC) Nucleus acts as a sensory organ for peripheral signals of energy status.**

# Control of food intake and energy expenditure




**Hypothalamus :**  
arcuate nucleus

**Neuropeptides :**

**Agouti-related protein and neuropeptide Y (stimulates food intake and inhibit energy expenditure)**

**Proiomelanocortin/ cocaine and amphetamine-regulated transcript (inhibit food intake and stimulate energy expenditure)**


# Role of arcuate nucleus neurons in adiposity signaling



# Phenotype of *ob/ob* TG mice

Body Mass (g)


Females



Weeks

Males

Body Mass (g)



Weeks

*ob/ob* (TG)

*ob/ob* (KO)


*ob/+* (TG)

*ob/+* (KO)



# Leptin : the 16-kDa hormonal product of the obesity (*ob*) gene

*Yang and Barouch, Circulation Research, 2007*



The primary physiological role of leptin is to communicate to the central nervous system (CNS) the abundance of available energy stores and to restrain food intake and induce energy expenditure.




The absence of leptin therefore leads to increased appetite and food intake that result in morbid obesity.

Notably, only rare cases of severe early childhood obesity have been associated with leptin deficiency.

The remainder of the obese population typically have elevated leptin levels. The failure of leptin to induce weight loss in these cases is thought to be **the result of leptin resistance (hyperleptinemia caused by deficit in the circulatory transport and/or in the signaling cascade).**

SOCS3 : suppressor of cytokine signaling

# Transdifferentiation from white fat cells to «beige» fat cells (brown-like adipocytes)



- **Polygenic trait : non mendelian quantitative phenotype**
- **Correlation factor BMI**
  
- **Twin pairs -**
- **Monozygotic twins : 0.74**
- **Dizygotic twins : 0.32**
  
- **Parental-**
- **Offspring : 0.19**
- **Adoptive : 0.06**

Speliote-E et al., Nature 2015, February 12; 518 (7538):197-206

## ARTICLE

+ interactions with Diet, Exercise, Epigenetics


doi:10.1038/nature14132

# New genetic loci link adipose and insulin biology to body fat distribution

A list of authors and their affiliations appears at the end of the paper

Body fat distribution is a heritable trait and a well-established predictor of adverse metabolic outcomes, independent of overall adiposity. To increase our understanding of the genetic basis of body fat distribution and its molecular links to cardiometabolic traits, here we conduct genome-wide association meta-analyses of traits related to waist and hip circumferences in up to 224,459 individuals. We identify 49 loci (33 new) associated with waist-to-hip ratio adjusted for body mass index (BMI), and an additional 19 loci newly associated with related waist and hip circumference measures ( $P < 5 \times 10^{-8}$ ). In total, 20 of the 49 waist-to-hip ratio adjusted for BMI loci show significant sexual dimorphism, 19 of which display a stronger effect in women. The identified loci were enriched for genes expressed in adipose tissue and for putative regulatory elements in adipocytes. Pathway analyses implicated adipogenesis, angiogenesis, transcriptional regulation and insulin resistance as processes affecting fat distribution, providing insight into potential pathophysiological mechanisms.

European Studies Only



- The study, involving more than 300,000 people, highlights 97 gene variants : 53 new genes affecting body mass.
- Many in the appetite control / basal metabolism
- Some people are addicted to food and find hard to suppress their appetite.
- The analysis reinforces the idea that weight is influenced by a very large number of genes each making a small contribution.
- Even the 97 genes variants shown to have the most powerful effect together only explain about 3% of the variation in BMI across the population.
- New development for therapies
- Evolution– the so-called “thrifty gene” hypothesis: **less energy for physical and mental exertion, storing energy in fat reserves would help during times of scarcity.**
- On the planet for the past five million years, but only had great food supplied for the past 100 years.
- We are not genetically ideally adapted to our environment today.

# Complex trait : cholesterolemia

## Variants with (partial) gain or loss of functions

*Combination of subtle gene changes add up to produce a disease trait*  
*Gene interactions : favorable, defavorable or neutral*

More or  
less active

Cholesterol

HMG-  
CoA  
reductase

LDL  
receptors


More or  
less  
abundant  
/ affinity

More or  
less  
affinity  
for DNA

PPAR $\alpha$   
Gene regulator


Leptin  
Hormone

More or  
less  
efficient



## 1) Point mutation in *GHRL* gene (Leu72Met)


Higher  
butyrylcholinesterase  
= inactivation




Ukkola et al., 2011, BCEM

## 2) SNP in *BDNF* gene

Brain-derived neurotrophic factor



Mou et al., 2015, Cell Reports



Non-digestible carbohydrates

Pre/probiotics

Synbiotics

*Akkermansia muciniphila*

High-fat diet

Low-fibers

Induce a  
dysbiosis

↗ Mucus thickness

↗ Reg3g

↘ Mucus thickness

↗ Gut barrier

↘ Gut barrier

Improved glucose  
and lipid metabolism


Altered glucose and  
lipid metabolism


↗ Metabolic endotoxemia  
↗ Inflammation




Healthy

Obesity  
Diabetes  
Steatosis







**Figure 2. Crosstalk between the gut microbiota, the endocannabinoid system, the apelinergic system and impacts of metabolic endotoxaemia on adipose tissue development.** In physiological situations, the endocannabinoid (eCB) system tone reduces the levels of apelin and apelin receptor (APJ) mRNA in adipose tissues, whereas the inflammatory tone increases these markers. Endocannabinoids increase the adipogenesis processes. In obesity, both the eCB system and the inflammatory tone are increased and associated with metabolic endotoxaemia (i.e. circulating lipopolysaccharide (LPS)). In this pathological condition, LPS completely abolished the effects of endocannabinoids on adipogenesis and the apelinergic system, suggesting that both eCBs and LPS are implicated in adipose tissue metabolism.

Treatment of obesity starts with comprehensive lifestyle management (diet, physical activity, behavior modification)

## **Reduction of caloric intake and physical activity**

**Reduction of 500-1000 kcal/day + 150 min of moderate activity and 75 min of intense activity/week**

Effective management of obesity must be based on a partnership between a highly motivated patient and a committed team of health professionals.

\* physician, a psychologist or psychiatrist, physical and exercise therapists, dietitians,

Gain : modest weight loss between 5% and 10% for the long-term- good for co-morbidities improvement.

**Diet, exercise, and behavioral modification** : should be included in all obesity management approaches for body mass index (BMI) of 25 kg/m<sup>2</sup> or higher.

**Pharmacotherapy (GLP-1 analogs, TZD : glitazones, metformin, ACE inhibitor,...)** : for BMI of 27 kg/m<sup>2</sup> or higher with comorbidity or BMI over 30 kg/m<sup>2</sup>

**Bariatric surgery** : for BMI of 35 kg/m<sup>2</sup> with comorbidity or BMI over 40 kg/m<sup>2</sup> : reduction of BM by 20-30 %-sustained.

# Stuart's Behavioral Approach : ABC Model



**Conventional Food**




**Very Low Calorie Diet**



**Decrease Intake  
Increase Energy Expenditure / Behavior  
Medication**

**Not Effective / Long Term**



overweight


obese

Treatment	BMI category				
	25–26.9	27–29.9	30–34.9	35–39.9	≥ 40
Lifestyle therapy: Diet, physical activity, and behavior therapy	With comorbidities	With comorbidities	+	+	+
Pharmacotherapy		With comorbidities	+	+	+
Surgery			With c o m o r b i d i t i e s		

- Prevention of weight gain with lifestyle therapy is indicated in any patient with a BMI  $\geq 25$  kg/m<sup>2</sup>, even without comorbidities, while weight loss is not necessarily recommended for those with a BMI of 25–29.9 kg/m<sup>2</sup> or a high waist circumference, unless they have two or more comorbidities.
- Combined therapy with a low-calorie diet (LCD), increased physical activity, and behavior therapy provide the most successful intervention for weight loss and weight maintenance.
- Consider pharmacotherapy only if a patient has not lost 1 pound per week after 6 months of combined lifestyle therapy.

The + represents the use of indicated treatment regardless of comorbidities.

*Serotonin and norepinephrine re-uptake inhibitor (SNRI) in the CNS increasing the sensation of satiety*




Adapted from Ryan DH, et al. *Obes Res.* 1995 (suppl.4): 553S-559S

Average weight loss: 5-10 % of the starting body weight after one year of treatment.

Adverse Effects: Increase in heart rate and blood pressure, headache, dry month, constipation and insomnia.

*Decreases fat absorption, inhibits pancreatic lipase*



Orlistat:

- with prescription (120 mg)
- without prescription (60 mg) + lifestyle therapy



Average weight loss: 5-10 % of the starting bodyweight after one year of treatment.

Adverse Effects: Decrease in absorption of fat-soluble vitamins, soft stools and bowel urgency and flatulence.

Risk of hepatic lesions and renal failure

# L'alimentation bio réduit le risque de surpoids et d'obésité

Rédaction en ligne

Mis en ligne mardi 26 avril 2016, 23h57

[Lire aussi : L'alimentation bio réduit le risque de surpoids et d'obésité](#)

## La méditation réduit le risque d'obésité

Le 04 décembre 2015 à 11h07 - Mis à jour le 04 décembre 2015 à 13h00 - par [Agathe Mayer](#)

 Partager 18

 Tweeter

 G+1 4

 COMMENTEZ

 JE M'ABONNE

**Les techniques de relaxation permettent de réduire le stress, et diminuer les risques de surpoids ou d'obésité par deux. Elles doivent être pratiquées régulièrement pour être efficaces.**

# Les Américains maigrissent très vite, mais c'est une Française qui a battu le record !

Mercredi, 27 Avril, 2016

Les journaux de l'autre côté de l'Atlantique décrivent les histoires de personnes obèses, qui ont perdu beaucoup de poids grâce à une méthode élaborée par des diététiciens du Minnesota. Même les femmes et les hommes les plus résistants aux régimes et aux exercices, en appliquant leur méthode, perdent de 10 à 14 kilos en un mois.

Cependant, jusqu'à présent le meilleur résultat revient à une française. Marie, 28 ans, n'a laissé aucune chance aux Américains - elle a perdu **24kg en moins de deux mois**, sans faire de régime ni d'exercices ! Malgré une perte de poids si drastique, elle reste en bonne santé, elle maintient un poids stable depuis 5 mois et elle est plus heureuse que jamais.



<http://actualitesendirect.com/33/sante/jai-senti-que-la-graisse-sevapore-de-mon->

Although obesity in itself is associated with increased morbidity and mortality, massive, poorly monitored weight loss and/or weight cycling can have equally dire consequences.

Among the important potential complications to watch out for in the setting of weight loss are the following:

**Cardiac arrhythmias**

**Electrolyte derangements** : Hypokalemia (low potassium  $< 3.5$  mEq/L)

**Hyperuricemia**


**Psychological sequelae** : Including depression and the development of eating disorders (particularly binge-eating disorders)

**Cholelithiasis** : Gallstones are concretions that form in the biliary tract, usually in the gallbladder

Thank you for your attention...

Time for questions...

## In summary: elongation/ saturation from palmitate



**Elongation** : saturated FA of longer chain by further addition of acetyl groups (FA elongation systems present in the **smooth ER** and **mitochondria**)

Palmitoyl-**CoA** ---> Stearoyl-**CoA**

Different enzymes (than in synthesis) and CoA rather than ACP but reactions are similar to the reactions involved in palmitate synthesis :

*\* donation of 2 C from malonyl-CoA followed by a reduction, a dehydration, and a reduction to the saturated 18-C product*

# Amino Acids

- Bacteria can synthesize all 20
- Mammals require some in diet

**TABLE 18-1**


**Nonessential and Essential Amino Acids for Humans and the Albino Rat**

	<b>Nonessential</b>	<b>Conditionally essential*</b>	<b>Essential</b>
<i>pyruvate</i> →	<b>Alanine</b>	<b>Arginine</b> ← <i>Urea cycle</i>	<b>Histidine</b>
	<b>Asparagine</b>	<b>Cysteine</b>	<b>Isoleucine</b>
<i>oxaloacetate</i> →	<b>Aspartate</b>	<b>Glutamine</b>	<b>Leucine</b>
<i>Alpha-ketoglutarate</i> →	<b>Glutamate</b> →	<b>Glycine</b>	<b>Lysine</b>
	<b>Serine</b>	<b>Proline</b>	<b>Methionine</b>
		<b>Tyrosine</b> ← <i>Urea cycle</i>	<b>Phenylalanine</b>
			<b>Threonine</b>
			<b>Tryptophan</b>
			<b>Valine</b>

\*Required to some degree in young, growing animals and/or sometimes during illness.

Table 18-1  
Lehninger Principles of Biochemistry, Sixth Edition  
© 2013 W. H. Freeman and Company

# Summary of Amino Acid Catabolism



**FIGURE 18–15 Summary of amino acid catabolism.**

Amino acids are grouped according to their major degradative end product. Some amino acids are listed more than once because different parts of their carbon skeletons are degraded to different end products. The figure shows the most important catabolic pathways in vertebrates, but there are minor variations among vertebrate species. Threonine, for instance, is degraded via at least two different pathways, and the importance of a given pathway can vary with the organism and its metabolic conditions. The glucogenic and ketogenic amino acids are also delineated in the figure, by color shading. Notice that five of the amino acids are both glucogenic and ketogenic. The amino acids degraded to pyruvate are also potentially ketogenic. Only two amino acids, leucine and lysine, are exclusively ketogenic.

# In rodents

## High Diet models

High fat-diet (60-70 %) / high carbohydrates (chow) / cafeteria diet

## Genetic models


GTG obese mice : GoldThioGlucose toxic for hypothalamus---> hyperphagia

*ob/ob* mice : mutation in leptin gene/X 6 / hyperphagia (stay leptin sensitive)

*db/db* mice : mutation in the leptin receptor (leptin resistant)

*ya* : Agouti protein ectopic expression mice ---> hyperphagia (regulated by leptin)

MC4R -/- : mutations in 3-5 % found in patients (BMI > 40)




Agouti-Agrp = antagonists MC4R

- promoter of the human AGRP and multiple regulatory elements, including two TATA boxes, one CCAAT box, and three CACCC boxes.

- two sites for the STAT transactivators.

- a polymorphism, A67T was identified in the third exon of the gene but it was not associated with obesity or type 2 diabetes clinical profiles.

**Excess of glucocorticoids produce visceral obesity and diabetes, but circulating glucocorticoid levels are normal in obese patients (*Mazuzaki et al., Science 2001*)**



Adrenal ---> cortisol \*---> cortisone

**Visceral obesity**

**Glucocorticoids can be produced locally from inactive 11-keto forms through the enzyme 11beta-hydroxysteroid dehydrogenase type-1 (11beta HSD-1). Transgenic mice overexpressing 11beta HSD-1 selectively in adipose tissue to an extent similar to that found in adipose tissue from obese humans.**

- \* increased adipose levels of cortisol
- \* visceral obesity that was exaggerated by a high-fat diet
- \* insulin-resistant diabetes
- \* hyperlipidemia
- \* hyperphagia despite hyperleptinemia

**Increased adipocyte 11beta-HSD-1 activity may be a common molecular etiology for visceral obesity and the metabolic syndrome.**

